Top Page
Oncolytics Biotech
(TSX:ONC)
Oncolytics Biotech (ONC) vs. iShares MSCI Canada ETF (EWC)
Oncolytics Biotech Business Overview & Revenue Model
Oncolytics Biotech Earnings Call Summary
Oncolytics Biotech Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -403.00K | -392.00K | -452.06K | -446.19K |
| EBITDA | -34.88M | -33.71M | -26.83M | -25.80M | -25.37M |
| Net Income | -31.71M | -27.75M | -24.84M | -26.30M | -19.55M |
Balance Sheet | |||||
| Total Assets | 20.19M | 38.82M | 37.33M | 45.88M | 34.35M |
| Cash, Cash Equivalents and Short-Term Investments | 15.94M | 34.91M | 32.14M | 41.26M | 31.22M |
| Total Debt | 1.06M | 423.00K | 373.00K | 654.75K | 402.06K |
| Total Liabilities | 14.20M | 11.26M | 10.83M | 9.78M | 9.59M |
| Stockholders Equity | 5.98M | 27.56M | 26.50M | 36.10M | 24.75M |
Cash Flow | |||||
| Free Cash Flow | -27.20M | -28.46M | -23.41M | -22.72M | -22.10M |
| Operating Cash Flow | -26.97M | -28.45M | -23.36M | -22.43M | -22.07M |
| Investing Cash Flow | -239.00K | 20.22M | -20.40M | -285.95K | -29.30K |
| Financing Cash Flow | 6.64M | 31.99M | 12.21M | 33.02M | 39.77M |
Oncolytics Biotech Technical Analysis
Oncolytics Biotech Risk Analysis
Oncolytics Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | C$71.84M | 18.62 | 14.51% | ― | 28.97% | ― | |
53 Neutral | C$57.02M | ― | -97.22% | ― | ― | -67.03% | |
52 Neutral | $7.61B | 0.10 | -63.03% | 2.08% | 16.34% | 0.32% | |
43 Neutral | C$19.31M | ― | -608.22% | ― | ― | 56.78% | |
43 Neutral | $147.80M | ― | -211.24% | ― | ― | 0.10% | |
33 Underperform | C$64.05M | ― | 248.46% | ― | ― | 32.71% | |
33 Underperform | C$77.12M | ― | 685.26% | ― | ― | -50.29% |
Oncolytics Biotech Corporate Events
Oncolytics Biotech announced it will present new data at the 2025 ASCO Annual Meeting, showcasing pelareorep’s effectiveness in activating immune responses in pancreatic ductal adenocarcinoma (PDAC), a challenging cancer with limited treatment options. The data supports the potential of pelareorep combination therapies to improve outcomes for patients with PDAC, reinforcing Oncolytics’ position in the oncology field and potentially impacting treatment approaches for this difficult-to-treat cancer.
Spark’s Take on TSE:ONC Stock
According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.
Oncolytics Biotech faces significant financial challenges, with persistent operational losses and a reliance on external financing. Despite technical indicators suggesting bearish momentum, clinical advancements in cancer treatments provide some optimism. The valuation is reflective of speculative biotech investments, with negative P/E and no dividend. Recent earnings call and corporate events offer potential upside through strategic developments but are overshadowed by leadership transitions and market value concerns. Overall, the stock remains speculative with potential upside contingent on successful clinical outcomes.
To see Spark’s full report on TSE:ONC stock, click here.
Oncolytics Biotech Inc. has entered into a share purchase agreement with Alumni Capital LP to secure up to $20 million in funding for the continued development of pelareorep. This strategic move allows Oncolytics to advance its clinical milestones while maintaining shareholder value, with the flexibility to control the timing and amount of equity sales.
Spark’s Take on TSE:ONC Stock
According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.
Oncolytics Biotech faces financial challenges with consistent operational losses and reliance on external financing. While technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The search for a new CEO and regulatory uncertainties pose additional risks. Overall, the stock is speculative with potential upside in successful clinical trials.
To see Spark’s full report on TSE:ONC stock, click here.
Oncolytics Biotech’s pelareorep was highlighted at an H.C. Wainwright event by key opinion leaders as a promising immunotherapy for breast and pancreatic cancers. The discussions emphasized pelareorep’s potential to improve treatment outcomes by activating the immune system, offering new hope for cancers resistant to current treatments. This recognition underscores Oncolytics’ strategic positioning in the oncology market, potentially enhancing its reputation and stakeholder interest as it progresses towards critical clinical milestones.
Spark’s Take on TSE:ONC Stock
According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.
Oncolytics Biotech faces financial challenges with consistent operational losses and reliance on external financing. While technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The search for a new CEO and regulatory uncertainties pose additional risks. Overall, the stock is speculative with potential upside in successful clinical trials.
To see Spark’s full report on TSE:ONC stock, click here.
Oncolytics Biotech has made significant progress in its pancreatic and anal cancer trials, strengthening its pipeline for 2025. The company received regulatory clearance from Germany’s Paul-Ehrlich-Institute to continue enrolling patients in its pancreatic cancer study, indicating positive safety reviews. Additionally, recent clinical data presented at the 2025 ASCO Gastrointestinal Cancers Symposium demonstrated pelareorep’s potential efficacy and safety in treating pancreatic and anal cancers. These developments de-risk pelareorep’s progression and could lead to larger clinical trials, potentially enhancing treatment options and creating shareholder value.
Oncolytics Biotech has announced key advancements in its pipeline for 2025, highlighting significant progress with its immunotherapy agent, pelareorep, in treating pancreatic and anal cancers, in addition to metastatic breast cancer. Recent regulatory and clinical developments, including safety clearance from Germany’s Paul-Ehrlich-Institute to advance a pancreatic cancer study, and promising data presented at the ASCO GI 2025 Symposium, underscore pelareorep’s potential in diverse cancer treatments. These milestones are expected to de-risk pelareorep’s development, potentially paving the way for larger clinical trials and advancing Oncolytics’ position in the oncology space, providing new treatment options for patients and creating value for shareholders.
Oncolytics Biotech Inc. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock has traded below $1.00 for 30 consecutive business days. The company has until August 12, 2025, to regain compliance, during which its shares will continue to trade on Nasdaq. If Oncolytics fails to meet the requirement by then, it may qualify for an additional compliance period. The notification does not immediately affect the company’s operations or stock listing, but it highlights the need to address market value concerns, potentially impacting investor confidence.
Oncolytics Biotech Inc. announced that Matt Coffey, Ph.D., will not return to his role as CEO after a medical leave of absence due to ongoing health concerns. Dr. Coffey’s decision was made with the best interests of his family and the company in mind. He has played a pivotal role in the development of pelareorep, an innovative therapeutic agent for cancer treatment, from its pre-clinical stages to Phase 2 studies. Wayne Pisano, the Chair of Oncolytics’ Board of Directors, will serve as interim CEO while the company searches for a new CEO to continue advancing Coffey’s vision. This leadership transition may impact Oncolytics’ strategic direction as it seeks to further its position in the oncology immunotherapy sector.